Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
125.59
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
June 30, 2025
From
Biogen Inc.
Via
GlobeNewswire
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
June 27, 2025
From
Biogen Inc.
Via
GlobeNewswire
What Does the Market Think About Biogen?
June 17, 2025
Via
Benzinga
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
June 25, 2025
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.
Via
Benzinga
Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday
June 25, 2025
Via
Benzinga
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
June 25, 2025
From
Biogen Inc.
Via
GlobeNewswire
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
June 25, 2025
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Via
Investor's Business Daily
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
June 22, 2025
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.
Via
Stocktwits
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
June 18, 2025
From
Biogen Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
June 16, 2025
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.
Via
Stocktwits
Topics
Government
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal
June 16, 2025
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.
Via
Benzinga
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
June 16, 2025
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space.
Via
Investor's Business Daily
Topics
ETFs
1 Profitable Stock with Exciting Potential and 2 to Avoid
June 13, 2025
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via
StockStory
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
June 12, 2025
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.
Via
Benzinga
Demystifying Biogen: Insights From 11 Analyst Reviews
June 12, 2025
Via
Benzinga
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
June 12, 2025
From
Biogen Inc.
Via
GlobeNewswire
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
June 03, 2025
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
May 29, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen...
Via
StockStory
Topics
Artificial Intelligence
Uncover the latest developments among S&P500 stocks in today's session.
May 29, 2025
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Via
Chartmill
Stay informed with the top movers within the S&P500 index on Thursday.
May 29, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Via
Chartmill
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
May 27, 2025
Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise
From
Biogen Inc.
Via
GlobeNewswire
What's going on in today's session: S&P500 movers
May 19, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...
Via
Chartmill
BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance
May 15, 2025
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above...
Via
StockStory
Topics
World Trade
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
May 14, 2025
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.
Via
Benzinga
Topics
Stocks
3 Cash-Producing Stocks Skating on Thin Ice
May 13, 2025
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
May 12, 2025
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...
Via
StockStory
Topics
Government
Stocks
World Trade
2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
May 06, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...
Via
StockStory
4 Stocks to Buy for a Potential “Summer Panic”
May 04, 2025
Luke Lango predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create...
Via
InvestorPlace
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
May 01, 2025
Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.
Via
Benzinga
Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
May 01, 2025
Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was...
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.